FDA Guidelines Seek to Speed Development of Antibacterial Drugs

Drug Industry Daily
Drug companies can streamline the development of new antibacterial drugs for seriously ill patients by applying less rigorous standards of effectiveness and more limited clinical trials than typical, the FDA said in guidance issued Aug. 1.

To View This Article:


Subscribe To Drug Industry Daily